Floatz logo

m3814

Metastatic Castration-Resistant Prostate Carcinoma

National Cancer Institute (NCI)Phase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Metastatic Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Golimumab
University of Washington
Phase 2CCC
Anti-Steap1 Car T-Cells
Fred Hutchinson Cancer Center
Phase 1/2CCC

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →